000			02966nam a22003975i 4500
003			ESmaUEC
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
040			_aES-MaUEC _bspa _cES-MaUEC
336			_aTexto _btxt _2rdacontent
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
999			_c107024 _d107024 _x1
001			107024
005			20230102113323.0
008			180404s2018 gw | s |||| 0|eng d
020			_a9783319751849
024	7		_a10.1007/978-3-319-75184-9 _2doi
050		4	_aRC280.L9 2018 EB
245	1	0	_aResistance of Targeted Therapies Excluding Antibodies for Lymphomas _cedited by Andrés J. M. Ferreri.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2018
300			_a1 recurso en línea (XIII, 138 páginas 14 ilustraciones,13 ilustraciones a color)
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v17
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aChapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.
520	3		_aIn the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance. .
650		7	_aLinfomas _2embne _9668066
650		7	_aCáncer _xInvestigación _2embne _9182523
700	1		_aFerreri, Andrés J. M. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iEdición impresa: _z9783319751832
776	0	8	_iEdición impresa: _z9783319751856
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-75184-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _b04/2019 _cm _dz _ek _feng _ggw _h0